Bone Hormones: Survival of the glycosylated

Osteocalcin is a bone matrix protein that acts like a hormone when it reaches the blood, and has different effects in mice and humans.
  1. Harry C Blair  Is a corresponding author
  2. Paul H Schlesinger
  1. Veterans Affairs Medical Center and the Department of Pathology, University of Pittsburgh, United States
  2. Department of Cell Biology and Physiology, Washington University School of Medicine, United States

Bone tissue is constantly being created and replaced in a process called remodeling. This involves cells called osteoblasts making bone and others cells called osteoclasts taking up the various minerals and proteins released from the degraded bone and discharging them into the blood (Figure 1). Osteocalcin is a protein found in bone tissue and is abundantly present in amounts equimolar to collagen – the structural protein of bone. Once absorbed by osteoclasts, osteocalcin displays variable carboxylation (the adding of a carboxyl acid group to the protein sequence) and is cleaved at various sites during its release.

How osteocalcin is synthesized and released into the blood.

The protein osteocalcin (red dots) resides in the bone matrix with collagen (green) and other matrix proteins integrated into mineralized bone. Bone tissue is broken down by cells called osteoclasts (shape outlined in blue), and left-over proteins – including osteocalcin – are partially degraded and discharged into the blood.

The osteocalcin molecules that reach the blood are a complex family of distinctive small peptides, most of which are less than 1000 kDa in weight (Blair et al., 1986). The family of discharged peptides include mixtures of intact or cleaved osteocalcin (Ivaska et al., 2004) and partially uncarboxylated protein (Poser and Price, 1979; Cairns and Price, 1994). These molecules behave like hormones, traveling to other organs in the body – such as the pancreas and liver – where they help to regulate metabolic processes (Tsuka et al., 2015).

It is widely posited that bone acts as endocrine organ that contributes to metabolic regulation (Dirckx et al., 2019). For example, knocking out the gene for osteocalcin in mice has been shown to impair glucose tolerance, to lead to increase bone formation, and to reduce testosterone production and muscle mass. However, these metabolic changes are variable and do not occur in all mouse models (Komori, 2020).

The G-protein receptor that osteocalcin binds to can also interact with numerous other ligands, such as calcium and steroids, which may be responsible for these differing observations (Pi et al., 2005). Furthermore, other hormones that bind to G-protein receptors, such as follicle stimulating hormone, have been found to activate receptors not on their target organ, and cause additional, unexpected effects (Sun et al., 2006). Together, this demonstrates the challenges associated with studying the function of osteocalcin, and why there is still a great deal to learn about the various roles of osteocalcin in mammals, including humans.

To coordinate metabolism in diverse tissues, the modified osteocalcin needs to be maintained at high levels in the blood and not be immediately removed by the kidney’s filtration system and discharged in the urine. Now, in eLife, Mathieu Ferron and co-workers from the Montreal Clinical Research Institute, the University of Montreal, the University of Copenhagen and McGill University – including Omar Al Rifai as first author – report how osteocalcin in mice is able to survive for longer in the blood than human osteocalcin (Al Rifai et al., 2020).

The team found that mouse osteocalcin undergoes an additional modification, which attaches a small sugar group called an O-glycan to a serine residue in the protein. Al Rifai et al. discovered that this sugar group prevented osteocalcin from being degraded by enzymes in the blood. Human osteocalcin was found to have a tyrosine residue at this site: however, when this was replaced with a serine residue, O-glycan groups were able to bind to the hormone and make it more stable, causing it to persist for longer in the blood. This difference in stability is likely what causes mice to have 5–10 times more osteocalcin in their blood than humans.

Much of what is known about the influence of osteocalcin on metabolism has come from experiments on mice. However, in addition to having different levels of osteocalcin, the molecular biology of this hormone also differs between humans and mice. In rodents, osteocalcin is coded by a cluster of three genes, two of which are expressed in osteoblasts (Moriishi et al., 2020), whereas human osteocalcin is coded by a single gene (Celeste et al., 1986).

Further work is needed to address other aspects of how osteocalcin is processed and regulated in humans. Previous studies suggest that levels of human osteocalcin are also regulated by the rate at which osteoclasts break down the bone’s tissue, and inhibiting this process has been found to reduce the amounts of osteocalcin in the blood by 30% (Zhou et al., 2020). However, the degradation of bone might not be the sole source of osteocalcin in humans (Figure 1), and some of our experiments suggest that when levels of osteocalcin are low, cells other than osteoblasts may also release moderate amounts of decarboxylated osteocalcin into the blood; but this remains to be established. This suggestion is supported by the fact that while decarboxylation in osteoclasts has not been fully studied, the process has been shown to be acid driven in vitro, and therefore unlikely to occur in osteoclasts (Poser and Price, 1979).

The findings of Al Rifai et al. demonstrate the challenges involved in extrapolating results about hormones and metabolism from mice to humans. Further work is still needed to fully understand the role of osteocalcin in humans, and to gain a clearer understanding of how levels of this hormone are regulated.

References

Article and author information

Author details

  1. Harry C Blair

    Harry C Blair is in the Veterans Affairs Medical Center and the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, United States

    For correspondence
    hcblair@pitt.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1152-3718
  2. Paul H Schlesinger

    Paul H Schlesinger is in the Department of Cell Biology and Physiology, Washington University School of Medicine, St Louis, United States

    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3268-7401

Acknowledgements

We acknowledge support from the Department of Veterans Affairs (Grant BX002490) and NIH (Grant AR-065407).

Publication history

  1. Version of Record published: January 22, 2021 (version 1)

Copyright

© 2021, Blair and Schlesinger

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 672
    views
  • 64
    downloads
  • 1
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Harry C Blair
  2. Paul H Schlesinger
(2021)
Bone Hormones: Survival of the glycosylated
eLife 10:e65719.
https://doi.org/10.7554/eLife.65719

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Roberto Efraín Díaz, Andrew K Ecker ... James S Fraser
    Research Article

    Chitin is an abundant biopolymer and pathogen-associated molecular pattern that stimulates a host innate immune response. Mammals express chitin-binding and chitin-degrading proteins to remove chitin from the body. One of these proteins, Acidic Mammalian Chitinase (AMCase), is an enzyme known for its ability to function under acidic conditions in the stomach but is also active in tissues with more neutral pHs, such as the lung. Here, we used a combination of biochemical, structural, and computational modeling approaches to examine how the mouse homolog (mAMCase) can act in both acidic and neutral environments. We measured kinetic properties of mAMCase activity across a broad pH range, quantifying its unusual dual activity optima at pH 2 and 7. We also solved high-resolution crystal structures of mAMCase in complex with oligomeric GlcNAcn, the building block of chitin, where we identified extensive conformational ligand heterogeneity. Leveraging these data, we conducted molecular dynamics simulations that suggest how a key catalytic residue could be protonated via distinct mechanisms in each of the two environmental pH ranges. These results integrate structural, biochemical, and computational approaches to deliver a more complete understanding of the catalytic mechanism governing mAMCase activity at different pH. Engineering proteins with tunable pH optima may provide new opportunities to develop improved enzyme variants, including AMCase, for therapeutic purposes in chitin degradation.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Marian Brenner, Christoph Zink ... Antje Gohla
    Research Article

    Vitamin B6 deficiency has been linked to cognitive impairment in human brain disorders for decades. Still, the molecular mechanisms linking vitamin B6 to these pathologies remain poorly understood, and whether vitamin B6 supplementation improves cognition is unclear as well. Pyridoxal 5’-phosphate phosphatase (PDXP), an enzyme that controls levels of pyridoxal 5’-phosphate (PLP), the co-enzymatically active form of vitamin B6, may represent an alternative therapeutic entry point into vitamin B6-associated pathologies. However, pharmacological PDXP inhibitors to test this concept are lacking. We now identify a PDXP and age-dependent decline of PLP levels in the murine hippocampus that provides a rationale for the development of PDXP inhibitors. Using a combination of small-molecule screening, protein crystallography, and biolayer interferometry, we discover, visualize, and analyze 7,8-dihydroxyflavone (7,8-DHF) as a direct and potent PDXP inhibitor. 7,8-DHF binds and reversibly inhibits PDXP with low micromolar affinity and sub-micromolar potency. In mouse hippocampal neurons, 7,8-DHF increases PLP in a PDXP-dependent manner. These findings validate PDXP as a druggable target. Of note, 7,8-DHF is a well-studied molecule in brain disorder models, although its mechanism of action is actively debated. Our discovery of 7,8-DHF as a PDXP inhibitor offers novel mechanistic insights into the controversy surrounding 7,8-DHF-mediated effects in the brain.